ViewRay (NASDAQ: VRAY) develops advanced radiation therapy technology for the treatment of cancer. Its system provides continuous soft-tissue imaging during treatment, using radiotherapy enabling clinicians to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. The company was founded in 2004 and is based in Denver, Colorado.
Expert Collections containing ViewRay
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ViewRay is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
ViewRay has filed 75 patents.
Magnetic resonance imaging, Radiation therapy, Neuroimaging, Nuclear magnetic resonance, Medical imaging
Magnetic resonance imaging, Radiation therapy, Neuroimaging, Nuclear magnetic resonance, Medical imaging
Latest ViewRay News
Nov 30, 2023
USD 2.93 Billion by 2032 | CAGR of 5.1% The Global Image-Guided Radiation Therapy Market Size was valued at USD 1.78 Billion in 2022 and the Worldwide Image-Guided Radiation Therapy Market Size is expected to reach USD 2.93 Billion by 2032, according to a research report published by Spherical Insights & Consulting. Companies Covered: Siemens Healthineers AG, Hitachi, Elekta, Koninklijke Philips, Viewray Technologies Inc., C-RAD, Varian Medical Systems, Toshiba Corporation, General Electric Healthcare Company, IBA Worldwide, Accuray Incorporated, Becton, Dickinson And Company, Vision RT Ltd. and Other Key vendors. November 30, 2023 05:00 ET Pune, INDIA New York, United States, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Global Image-Guided Radiation Therapy Market Size is to Grow from USD 1.78 Billion in 2022 to USD 2.93 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 5.1% during the projected period. The growing demand for image-guided interventions, as well as the expansion of non-invasive cancer management treatments, are some of the factors driving the growth of the image-guided radiation therapy market. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/2730 IGRT is a cutting-edge technology that precisely targets and treats cancerous tumors by combining radiation therapy with advanced imaging techniques. This method improves radiation therapy accuracy and effectiveness while minimizing damage to healthy tissues in the surrounding area. In IGRT, real-time imaging such as X-rays, CT scans, or MRI are used to guide radiation therapy delivery. It allows oncologists to monitor and adjust a patient's treatment plan as anatomy or tumor position changes during treatment. The global IGRT market is being driven by the increasing incidence of cancer worldwide, the growing demand for personalized treatment plans, and technological advancements in both imaging and radiation therapy equipment. This market includes a wide range of components, such as imaging systems, software solutions, and radiation therapy machines, all of which contribute to overall patient outcomes improvements. Implementing IGRT in healthcare facilities necessitates a substantial capital outlay. This includes the purchase of specialized imaging-capable linear accelerators and advanced imaging devices for IGRT. Many healthcare institutions, particularly those in resource-constrained areas or with smaller facilities, may find these initial costs prohibitively expensive. Browse key industry insights spread across 210 pages with 100 market data tables and figures & charts from the report on the " Global Image-Guided Radiation Therapy Market Size, Share, and COVID-19 Impact Analysis, By Product (4D RT, LINAC, MRI-guided radiotherapy, Portal CT Imaging), By Procedure (IMRT, Stereotactic, Particle), By Application (Neck, Prostate, Breast cancer), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032." Buy Now Full Report: https://www.sphericalinsights.com/checkout/2730 The MRI-guided radiotherapy segment is expected to hold a significant share of the global image-guided radiation therapy market during the forecast period. The global image-guided radiation therapy market is divided into four segments based on product: 4D RT, LINAC, MRI-guided radiotherapy, and Portal CT Imaging. MRI-guided radiotherapy is projected to account for a sizable portion of the global image-guided radiation therapy market during the forecast period. MRI integration enables timely assessment of treatment response, allowing providers to quickly adapt plans. This improves outcomes and intervention precision. Real-time insights improve decision-making and raise awareness of IGRT, which is consistent with patient-centric values. The stereotactic segment is expected to grow at the rapid pace in the global image-guided radiation therapy market during the forecast period. The global image-guided radiation therapy market is classified into three types based on the procedure: IMRT, stereotactic, and particle. The stereotactic segment, among these, is projected to expand at the fastest rate in the global image-guided radiation therapy market throughout the forecast period. Stereotactic therapy's efficiency in requiring fewer treatment sessions than conventional methods aligns with IGRT's streamlined approach. This benefits patients, healthcare providers, and resource allocation, which improves patient satisfaction and adherence. Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/2730 North America is anticipated to hold the largest share of the global Image-Guided Radiation Therapy market over the predicted timeframe. North America is expected to maintain the largest share of the global image-guided radiation therapy market in the coming years. North America, which included the United States and Canada, dominated the largest share of the image-guided radiation therapy market in 2022. With its robust healthcare infrastructure and access to cutting-edge medical technologies, North America is an ideal setting for the widespread use of advanced treatment methodologies like image-guided radiation therapy (IGRT). During the forecast period, Asia Pacific is projected to expand at a significant rate in the global image-guided radiation therapy market. The Asia-Pacific region, which includes China, Japan, India, and other countries, is experiencing rapid growth in the IGRT market. Population growth, rising cancer cases, and the development of healthcare infrastructure are all contributing factors to this expansion. Some APAC countries, most notably China and India, are establishing themselves as important IGRT markets. Competitive Analysis: The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major vendors in the Global Image-Guided Radiation Therapy Market include Siemens Healthineers AG, Hitachi, Elekta, Koninklijke Philips, Viewray Technologies Inc., C-RAD, Varian Medical Systems, Toshiba Corporation, General Electric Healthcare Company, IBA Worldwide, Accuray Incorporated, Becton, Dickinson And Company, Vision RT Ltd. and Others. Get Discount At @ https://www.sphericalinsights.com/request-discount/2730 Recent Developments In April 2023, the introduction of Pixxoscan expands GE HealthCare's portfolio of Magnetic Resonance Imaging (MRI) contrast agents, giving customers access to two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol). Market Segment This study forecasts revenue at global, regional, and country levels from 2020 to 2032. Spherical Insights has segmented the Global Image-Guided Radiation Therapy Market based on the below-mentioned segments: Global Image-Guided Radiation Therapy Market, By Product 4D RT IMRT Neck North America
ViewRay Frequently Asked Questions (FAQ)
When was ViewRay founded?
ViewRay was founded in 2004.
Where is ViewRay's headquarters?
ViewRay's headquarters is located at 1099 18th Street, Denver.
What is ViewRay's latest funding round?
ViewRay's latest funding round is Bankrupt/Admin.
How much did ViewRay raise?
ViewRay raised a total of $217.34M.
Who are the investors of ViewRay?
Investors of ViewRay include ViewRay Technologies, CRG, OrbiMed Advisors, F-Prime Capital, Kearny Venture Partners and 10 more.
Who are ViewRay's competitors?
Competitors of ViewRay include Monteris Medical, TNI medical, Augmenix, HyperMed Imaging, CardioInsight Technologies and 7 more.
Compare ViewRay to Competitors
Radiation Shield Technologies (RST) is the world leader in the research, design and production of personal protection systems for ionizing and nuclear radiation. The company's core technology, DemronTM , is specifically engineered to combine radiation protection with "ease of use" in order to maximize effective radiological defense. RST's primary goal is to ensure that all DemronTM products are of the highest protective quality. This is achieved by working closely with the company's end users, developing new standards of personal radiation protection, and meeting the specific needs of those groups most at risk of exposure. After almost a decade of development, RST is proud to introduce DemronTM to the industries, governments and everyday people who, until now, have had no options for true personal radiation protection.n
Smart Animal is a medical devices company developing prototypes to enable patient-specific imaging and targeted therapy.
Calypso Medical provides technologies in the radiation oncology market
Civatech Oncology is a medical device company focused on the development of polymer-based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for the encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy. CivaTech Oncology was founded in 2006 and is based in Durham, North Carolina.
Swissray has been recognized as the industry's true pioneer in the design, manufacture and marketing of direct digital Radiography ddR technology. Delivering high quality radiographic images in just seconds, Swissray's single detector technology aims to improve overall productivity, and lowers the cost of general radiography in comparison to conventional or computed radiography.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.